Biotech News
LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows
LifeStance Health, one of the nation's largest providers of outpatient mental healthcare, is expanding access to two specialty services for treatment-resistant depression – esketamine1 (Spravato) and transcranial magnetic stimulation2 (TMS) – as separate analyses show meaningful reductions in depression symptoms and suicidal ideation among patients receiving each treatment.
